Every letter we have printed

What is not studied at all is what happens when somebody maintains for years and then has to stop for reasons outside their control. Every account of stopping in the literature is a planned stop, and planned stops are the minority case here.

The trial designs answer a question about the drug and the reader has a question about themselves. A mean regain curve tells an individual very little about their own trajectory, and the variance around those means is rarely printed with the same prominence.

Endoscopy has its own considerations distinct from general anaesthesia, and the two get merged in most coverage. Residual gastric contents affect the procedure itself and not only the airway question.

Blanket extended fasting for everybody on these agents was never proportionate and it cancelled procedures. The move towards stratified advice is a real improvement and it deserves to be reported as one rather than as a retreat.

Slower escalation as an alternative to stopping is the option that most often gets skipped, and the trial protocols permitted it. Presenting the choice as continue or stop leaves out the middle that the evidence base itself used.

Where a trial permits a dose reduction, the reported tolerability figures describe a population that adjusted, not a population that persisted. It is a reasonable protocol and it means the headline rate is not a rate at the nominal dose.

A publication covering this area sensibly cannot do more than describe how the literature classifies severe events and point the reader at proper clinical guidance. Your piece does that and resists the temptation to go further, which I think is the correct editorial position.

Adding glucagon agonism to increase energy expenditure is elegant and it is also the limb that has to be balanced most carefully, because the same receptor raises hepatic glucose output. The ratio between the components is the whole design problem and it is quoted far too casually.

Naming conventions have made this worse. A compound described by its number of targets tells you nothing about the balance between them, and the number has become a marketing property rather than a pharmacological one.

Your piece states that moving the injection day does not change total exposure, and I accept the arithmetic, but I want to record that it changed my experience considerably. I moved from Monday morning to Thursday evening and the two worst days now fall on a weekend. The drug is doing the same thing; my week is not.

Retest date and expiry date are different concepts and the trade uses them interchangeably. A retest date says the material may be re-examined and used if it still conforms; an expiry says it may not. Printing one and meaning the other is a small dishonesty that has become a convention.

Arrival condition should be recorded by the buyer at the moment of opening, in writing, with a photograph. It takes a minute and it is the only record of that leg that will ever exist.

Adsorption to the vial wall is the loss mechanism nobody thinks about, and it matters most at exactly the low concentrations people prepare. Material can leave a solution without degrading at all.

Nobody measures what they have after storage, which is the only way any of this would be settled. A determination on a solution held for four weeks would produce more information than every discussion thread on the subject combined.

The diluent is the variable nobody records. Bacteriostatic and plain water produce solutions with different chemistry and different in-use expectations, and accounts of stability in this market rarely state which was used.

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

The mechanistic account is assembled from studies in different species, at different exposures, on different endpoints, and it is presented as one continuous story. Each join in that chain is an inference and none of them is flagged.

Baseline variation in transit time across a healthy population is wide enough to swamp small effects, and studies with modest sample sizes are therefore measuring a difference against a very noisy background. Confidence intervals in this literature are wide for good reasons.

Deamidation at asparagine is the dominant route for several of these sequences and it is strongly pH dependent, which makes the reconstitution diluent a stability decision rather than a convenience one. Bacteriostatic water is not neutral in this respect and very few people treat it as a variable.

Freeze-thaw deserves its own warning. Repeated cycling concentrates solutes at the ice interface and is far harder on a reconstituted solution than a steady temperature a few degrees higher. The domestic freezer door is the worst place in the house for this material and the place most people put it.

Nobody measures what they have after storage, which is the only way any of this would be settled. A determination on a solution held for four weeks would produce more information than every discussion thread on the subject combined.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

In-use figures quoted in this market trace back, when you follow them, to manufacturer statements about a different formulation of a different product. The chain of citation is worth publishing on its own.

Bone density in these studies is reported over horizons far shorter than the timescale on which bone remodels. A twelve-month change is a signal about an early phase of a slow process, and it is read as a conclusion about the process.

Turnover markers are cheaper, faster and more responsive than imaging, and they are collected in a minority of these studies. They answer a different question and they answer it inside a trial horizon.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

Resistance training during an energy deficit attenuates lean tissue loss rather than preventing it, and the honest framing is attenuation. Overstating what training can achieve sets an expectation that the evidence does not support and that people then blame themselves for missing.

The follow-up periods in these studies are shorter than the period readers care about. Reporting that plainly, rather than extending the observed trajectory in the reader’s imagination, is the honest treatment and your piece does it.

The run-in period does a lot of work in these designs and is rarely described in coverage. Everybody in the randomised phase has already demonstrated tolerance and response, and the population is therefore selected before the interesting part begins.

I would add a field for what was not tested. Certificates are read as complete accounts of a material, and the reason they are not is invisible: everything absent is absent silently. A line reading "sterility and endotoxin not determined" would be more informative than half the values above it.

Your anatomy diagram should mark which fields are assertions by the manufacturer and which are results from an instrument. On most certificates they sit in the same table in the same typeface, and a reader has no way to tell a measurement from a claim.

Nine years buying research chemicals and I had never once looked at the date of manufacture. I checked eleven certificates in my drawer this evening. Four do not carry one.

A note on the chain between synthesis and certificate. The document that matters is the one that names who took the sample and when. A report on a sample the seller chose, packed and posted describes that sample honestly and describes the lot only by assumption, and the assumption is the part nobody writes down.

Every certificate I hold has a header with a company name and no company address. It is a small thing until you need to write to somebody, at which point the document has told you who did the work and given you no means of reaching them.

Bariatric surgical cohorts are the other borrowed population and the mechanism differs substantially. Findings that follow from altered anatomy do not automatically follow from reduced intake, and the two literatures are frequently quoted side by side as though they were one.

A great deal of the advice circulating in this area comes from athletic populations in energy balance, and the transfer to a substantial deficit in a very different population is rarely acknowledged. Naming the source population every time is the simplest corrective available.

Comparison tables in this area are assembled from papers that used different assays, different cell lines and different readouts, and the resulting column of numbers looks like a measurement series. It is a collection of unrelated measurements formatted as one.

Biased signalling is the part of this literature that has moved most in the last few years and is barely present in general coverage. A receptor with more than one downstream pathway can be engaged differently by two ligands with identical binding.

As a community pharmacist I would add one thing to your section on missed doses: the label window matters less than whether the patient then double-doses to "catch up". I have seen that twice this year and both times the patient believed they were following instructions.

You describe biased agonism as "legitimate and probably important" and then decline to say which molecules are biased in which direction. That is a strange place to stop.